BETA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Beta Drugs Receives Dcgi Approval For Methotrexate Oral Solution
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
RECEIVES DCGI APPROVAL FOR METHOTREXATE ORAL SOLUTION
Source text: ID:nNSE4L8P0Y
Further company coverage: BTAD.NS
(([email protected];))
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
RECEIVES DCGI APPROVAL FOR METHOTREXATE ORAL SOLUTION
Source text: ID:nNSE4L8P0Y
Further company coverage: BTAD.NS
(([email protected];))
Beta Drugs To Consider Raising Of Funds
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
BETA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nNSE3QJk0Q
Further company coverage: BTAD.NS
(([email protected];))
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
BETA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nNSE3QJk0Q
Further company coverage: BTAD.NS
(([email protected];))
Beta Drugs To Write Off Investment Made Amounting $88,000 In Beta Ubk. International
Nov 7 (Reuters) - Beta Drugs Ltd BTAD.NS:
APPROVED TO WRITE OFF INVESTMENT MADE BY CO AMOUNTING 88,000 US DOLLARS IN BETA UBK. INTERNATIONAL
Source text for Eikon: ID:nNSE5ccL40
Further company coverage: BTAD.NS
(([email protected];))
Nov 7 (Reuters) - Beta Drugs Ltd BTAD.NS:
APPROVED TO WRITE OFF INVESTMENT MADE BY CO AMOUNTING 88,000 US DOLLARS IN BETA UBK. INTERNATIONAL
Source text for Eikon: ID:nNSE5ccL40
Further company coverage: BTAD.NS
(([email protected];))
Beta Drugs's Baddi Oncology Manufacturing Plant Receives ANVISA Approval
April 20 (Reuters) - Beta Drugs Ltd BTAD.NS:
CO'S ONCOLOGY MANUFACTURING PLANT RECEIVES ANVISA APPROVAL
ANVISA NOD FOR ORAL SOLIDS, INJECTABLES FORMULATIONS
Source text for Eikon: ID:nNSE1PWMP4
Further company coverage: BTAD.NS
(([email protected];))
April 20 (Reuters) - Beta Drugs Ltd BTAD.NS:
CO'S ONCOLOGY MANUFACTURING PLANT RECEIVES ANVISA APPROVAL
ANVISA NOD FOR ORAL SOLIDS, INJECTABLES FORMULATIONS
Source text for Eikon: ID:nNSE1PWMP4
Further company coverage: BTAD.NS
(([email protected];))
Upcoming Events:
Quarterly Results
Events:
Bonus
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Beta Drugs do?
Beta Drugs, a part of Adley Group, specializes in manufacturing oncology products like anti-cancer tablets, capsules, injections, and lyophilized injections. With a portfolio of over 50 products, it caters to the treatment of various cancer diseases.
Who are the competitors of Beta Drugs?
Beta Drugs major competitors are Bliss GVS Pharma, Novartis, Syncom Formulations, Jagsonpal Pharma, Indoco Remedies, Panacea Biotec, Lincoln Pharma. Market Cap of Beta Drugs is ₹1,873 Crs. While the median market cap of its peers are ₹1,655 Crs.
Is Beta Drugs financially stable compared to its competitors?
Beta Drugs seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Beta Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Beta Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Beta Drugs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory
How strong is Beta Drugs balance sheet?
Balance sheet of Beta Drugs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Beta Drugs improving?
Yes, profit is increasing. The profit of Beta Drugs is ₹42.42 Crs for TTM, ₹36.44 Crs for Mar 2024 and ₹30.72 Crs for Mar 2023.
Is the debt of Beta Drugs increasing or decreasing?
Yes, The net debt of Beta Drugs is increasing. Latest net debt of Beta Drugs is -₹14.32 Crs as of Mar-25. This is greater than Mar-24 when it was -₹42.15 Crs.
Is Beta Drugs stock expensive?
Beta Drugs is not expensive. Latest PE of Beta Drugs is 44.14, while 3 year average PE is 44.19. Also latest EV/EBITDA of Beta Drugs is 18.27 while 3yr average is 18.96.
Has the share price of Beta Drugs grown faster than its competition?
Beta Drugs has given better returns compared to its competitors. Beta Drugs has grown at ~40.16% over the last 8yrs while peers have grown at a median rate of 7.87%
Is the promoter bullish about Beta Drugs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Beta Drugs is 66.73% and last quarter promoter holding is 66.73%.
Are mutual funds buying/selling Beta Drugs?
There is Insufficient data to gauge this.
